Center for Immunity and Immunotherapies
Harnessing the Power of the Immune System
-
Rapidly Identifying Immune Diseases
Our experts developed unique approaches to rapidly identify immune diseases. We provide testing services for patients worldwide.
-
We Need Your Help
Private donors can help us create a brighter future for children with immune disorders.
Publications
Engineering and Flow-Cytometric Analysis of Chimeric LAGLIDADG Homing Endonucleases from Homologous I-OnuI-Family Enzymes. Baxter SK, Scharenberg AM,Lambert AR. Methods Mol Biol. 2014;1123:191-221. doi: 10.1007/978-1-62703-968-0_14.
The T-cell-dependent antibody response assay in nonclinical studies of pharmaceuticals and chemicals: Study design, data analysis, interpretation. Lebrec H, Molinier B, Boverhof D, Collinge M, Freebern W, Henson K, Mytych DT, Ochs HD, Wange R, Yang Y, Zhou L, Arrington J, Christin-Piché MS, Shenton J. Regul Toxicol Pharmacol. 2014 Feb 22. pii: S0273-2300 (14)00032-4. doi: 10.1016/j.yrtph.2014.02.008.
A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. Dai X, James RG, Habib T, Singh S, Jackson S, Khim S, Moon RT, Liggitt D, Wolf-Yadlin A, Buckner JH, Rawlings DJ. J Clin Invest. 2013 May 1;123 (5):2024-36. doi: 10.1172/JCI66963.
See more publications from the Center for Immunity and Immunotherapies
Latest News
- Using Gene Therapy to Build an Immune System in Newborns Without One
8.28.18 – On the Pulse
Seattle Children’s recently opened a clinical trial that is seeking a potentially safer, less aggressive and equally effective path to a cure by using a novel gene therapy to fix the faulty gene that causes the most common type of severe combined immunodeficiency (SCID). - Casebia Therapeutics Announces License and Collaboration Agreements With Seattle Children’s Research Institute
9.27.17 – Press Release
Casebia Therapeutics, a leading genetic engineering company, and Seattle Children’s Research Institute today announced an exclusive license agreement and research collaboration to explore new methods to treat and prevent autoimmune disease using CRISPR/Cas9 gene-edited regulatory T cells (Tregs) – a type of white blood cell that controls and modulates the body’s immune response. - Seattle Children’s Researchers Pioneer Gene Editing that Kills, Resists HIV
9.30.15 – Seattle Children’s On the Pulse
Drs. David Rawlings and Andrew Scharenberg found that gene editing could be used to engineer T cells that resist HIV infection and kill HIV-infected T cells or B-cell tumors. The discovery could help scientists working toward cures for HIV, cancer and other diseases.
Read more news about the Center for Immunity and Immunotherapies
